HomeAI · summaries
Storia in 5 fonti
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Theravance, after clinical setbacks, agrees to $929M buyout
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
- ·
morningstar.com
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
- ·
endpoints.news
Zymeworks to acquire troubled biotech Theravance in $929M deal
Zymeworks to acquire Theravance Biopharma for $929M, gaining rights to COPD drug Yupelri's US profit share and ex-US royalties generating ~$60M annually.
- ·
benzinga.com
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition - Theravance Biopharma (NASDAQ
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
- ·
fiercepharma.com
Zymeworks acquires struggling Theravance for $929M
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up…